Tech Company Financing Transactions
Alessa Therapeutics Funding Round
Mission BioCapital and Johnson & Johnson Development Corporation participated in a $15 million Seed funding round for Alessa Therapeutics. The round was announced on 12/13/2024.
Transaction Overview
Company Name
Announced On
12/13/2024
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Seed
Investors
Mission BioCapital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance development of its lead program, Enolen®, a novel enzalutamide-eluting seed implant for the treatment of localized prostate cancer.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
930 Brittan Avenue
San Carlos, CA 94070
USA
San Carlos, CA 94070
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Founded by Pamela Munster and her group at the UCSF Department of Medicine -- division of Hematology and Oncology, Alessa is motivated by a shared goal: to create innovative advancements in oncology and the treatment of solid organ diseases. Alessa Therapeutics is focused on developing effective therapy delivered selectively to the prostate.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cam Gallagher
Chief Scientific Officer
Pamela Munster
Chief Technical Officer
Maithili Rairkar
VP - Bus. Development
Zach Collins
VP - Regulatory Affairs
Bonnie Wettersten
Browse more venture capital transactions:
Prev: 12/13/2024: Bpacks venture capital transaction
Next: 12/13/2024: Archer venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs